We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

134 hedge funds and large institutions have $334M invested in Karyopharm Therapeutics in 2021 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 58 increasing their positions, 34 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 34

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.17% less ownership

Funds ownership: 5.24% → 5.07% (-0.17%)

12% less funds holding

Funds holding: 153 → 134 (-19)

45% less capital invested

Capital invested by funds: $608M → $334M (-$273M)

58% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 33

72% less call options, than puts

Call options by funds: $2.28M | Put options by funds: $8.13M

Holders
134
Holders Change
-19
Holders Change %
-12.42%
% of All Funds
2.35%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
14
Increased
58
Reduced
34
Closed
33
Calls
$2.28M
Puts
$8.13M
Net Calls
-$5.85M
Net Calls Change
+$3.66M

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$15.2M
2
Renaissance Technologies
Renaissance Technologies
New York
+$3.3M
3
UBS Group
UBS Group
Switzerland
+$2.18M
4
Two Sigma Investments
Two Sigma Investments
New York
+$1.73M
5
Morgan Stanley
Morgan Stanley
New York
+$1.73M

Top Sellers

Rank Fund Capital Flow
1
HRCM
Hood River Capital Management
Florida
-$8.28M
2
GIM
Granahan Investment Management
Massachusetts
-$7.55M
3
JGC
J. Goldman & Co
New York
-$6.56M
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$6.15M
5
RCMNY
Rubric Capital Management (New York)
New York
-$6.07M
Name Holding Trade Value Shares
Change 		Change in
Stake
Macquarie Group
26
Macquarie Group
Australia
$2.22M – – –
Rafferty Asset Management
27
Rafferty Asset Management
New York
$2.16M +$818K +7,881 +47%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$1.76M +$93.1K +897 +5%
PPA
29
Parametric Portfolio Associates
Washington
$1.71M +$835K +8,044 +70%
Jennison Associates
30
Jennison Associates
New York
$1.57M +$940K +9,057 +101%
BC
31
Birchview Capital
Vermont
$1.43M +$111K +1,067 +7%
Citigroup
32
Citigroup
New York
$1.42M -$1.01M -9,718 -37%
Bank of America
33
Bank of America
North Carolina
$1.37M +$3.43K +33 +0.2%
Deutsche Bank
34
Deutsche Bank
Germany
$1.31M -$14.5K -140 -0.9%
Citadel Advisors
35
Citadel Advisors
Florida
$1.28M +$67K +645 +5%
Balyasny Asset Management
36
Balyasny Asset Management
Illinois
$1.17M +$1.04M +10,051 +304%
Tudor Investment Corp
37
Tudor Investment Corp
Connecticut
$1.12M +$776K +7,477 +139%
Charles Schwab
38
Charles Schwab
California
$1.1M -$1.92M -18,461 -60%
GCP
39
GSA Capital Partners
United Kingdom
$1.03M +$1.02M +9,857 +507%
SFI
40
Susquehanna Fundamental Investments
Pennsylvania
$840K +$433K +4,170 +77%
AA
41
AlphaCentric Advisors
Puerto Rico
$792K +$377K +3,634 +67%
Allianz Asset Management
42
Allianz Asset Management
Germany
$774K +$104K +1,001 +13%
Barclays
43
Barclays
United Kingdom
$770K -$459K -4,426 -33%
Swiss National Bank
44
Swiss National Bank
Switzerland
$766K – – –
VRS
45
Virginia Retirement Systems
Virginia
$712K +$684K +6,586 +420%
AllianceBernstein
46
AllianceBernstein
Tennessee
$674K – – –
RhumbLine Advisers
47
RhumbLine Advisers
Massachusetts
$560K -$204K -1,966 -23%
CSS
48
Cubist Systematic Strategies
Connecticut
$559K +$339K +3,266 +104%
State of Wisconsin Investment Board
49
State of Wisconsin Investment Board
Wisconsin
$555K – – –
California State Teachers Retirement System (CalSTRS)
50
California State Teachers Retirement System (CalSTRS)
California
$512K -$78.5K -756 -11%
1
2
3 4 5

KPTI Hedge Fund Activity: Q3 2021 in Review

134 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q3 2021, worth a combined $334M — down 45% from $608M a quarter earlier.

Sellers outnumbered buyers: 33 funds closed out of KPTI and 14 opened new positions — a net loss of 19 holders — while 34 trimmed existing stakes and 58 added.

The largest buyer was State Street, adding an estimated $15.2M. The largest seller was Hood River Capital Management, exiting entirely with an estimated $8.28M sold.

  • 134 institutional investors held Karyopharm Therapeutics (KPTI) as of Q3 2021, down from 153 in Q2 2021.
  • Funds reported $334M of Karyopharm Therapeutics stock for Q3 2021, down 45% quarter-over-quarter.
  • 14 funds opened new Karyopharm Therapeutics positions in Q3 2021 and 33 closed out, a net change of -19 holders.
  • The largest Karyopharm Therapeutics buyer in Q3 2021 was State Street, an estimated $15.2M added.
  • The largest Karyopharm Therapeutics seller in Q3 2021 was Hood River Capital Management, an estimated $8.28M sold.

Based on aggregated 13F filings for Q3 2021.